Digital Health, Technology & Innovation

Remedy Meds to Acquire Thirty Madison, Boosting Telehealth

Combination pairs leading brands: Remedy Meds, Keeps, Nurx, and Cove, with a nationwide clinician and pharmacy network to expand access to high-demand, digitally scalable treatments.

Remedy Meds, LLC, a consumer virtual-care and pharmacy platform, today announced it has entered into a definitive agreement to acquire Thirty Madison, Inc. (“Thirty Madison”). The transaction creates a larger, multi-brand platform across women’s, men’s, and metabolic health.

The transaction, which is valued just north of $500M, will be funded through an all-stock deal. Closing is expected in Q4 2025, subject to customary closing conditions and regulatory review.

Strategic Rationale

  • Scaled, multi-brand platform. Combines Remedy Meds (weight loss), Keeps (men’s hair loss), Nurx (women’s health), and Cove (migraine) under one consumer-centric platform with cross-category trust and funnel efficiency.
  • Integrated care & pharmacy. Nationwide clinician coverage, insurance coverage, and an integrated pharmacy fulfillment network support same-day video visits, rapid prescription review, tailored treatment plans, and direct-to-door delivery.
  • Robust financial performance. Remedy Meds today sits at $450M+ in annual revenue with substantial profitability, allowing Thirty Madison’s profitable, $220M+ revenue business to benefit from the financials of a scaled operating platform.

Executive Quotes

“By bringing together Thirty Madison’s trusted brands with Remedy Med’s acquisition engine, retention system, and pharmacy infrastructure, we will broaden access, shorten time-to-treatment, and maintain the financial discipline that has defined our growth,” said Haris Memon, Founder and CEO of Remedy Meds.

“Thirty Madison and Remedy Meds share a belief that patients deserve a better healthcare experience. Together we will deliver on making high-quality specialty care easier to access for millions of patients across the conditions we serve. I’m grateful to our teammates, clinicians, and partners who made this possible — and incredibly excited for what we’ll build together in this next stage of growth as a part of Remedy Meds,” said Demetri Karagas, CEO and Co-Founder of Thirty Madison.

Related posts

BenevolentAI Proposes Delisting via Merger with Osaka Holdings

Business Wire

OcuSciences Gets FDA Clearance for OcuMet Beacon in Retinal Health

Business Wire

Aclarion Expands to Santa Monica with MICSC

GlobeNewswire